Skip to main content
. 2019 Jun 5;104(11):5253–5262. doi: 10.1210/jc.2018-02703

Table 4.

Proportion of Individuals Achieving Predefined Lipid Goals at W24 (On-Treatment Population)

Alirocumab (n = 92) Placebo (n = 48)
Non–HDL-C <100 mg/dL 83 (90.2) 10 (20.8)
LDL-C <70 mg/dL 80 (87.0) 8 (16.7)
LDL-C <70 mg/dL and non–HDL-C <100 mg/dL 79 (85.9) 6 (12.5)

Data reported as n (%).